MILESTONE SCIENTIFIC INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MILESTONE SCIENTIFIC INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.41M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.43M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.79M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $4.90M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $6.31M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.72M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.43M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.97M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.31M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.72M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.71M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.93M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($8.71M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($6.82M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.34M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.52M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($7.43M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.19M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.95M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.70M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.11M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($8.83M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($7.38M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.45M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.00M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($8.00M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.23M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($6.51M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $449.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $858.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $701.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $878.2K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $307.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $189.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $245.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $272.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.27M | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.58M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.30M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $13.14M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $12.51M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.74M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $10.67M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $9.53M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $10.65M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.93M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $11.55M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.92M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.92M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($5.33M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($6.03M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($4.03M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($6.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.78M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.63M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.23M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.40M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.1K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.1K | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | $8.5K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $15.2K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $21.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $9.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $7.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $15.3K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $67.6K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.81M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.80M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.37M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.70M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $19.81M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.56M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.40M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $15.63M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $14.18M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.36M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.70M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.59M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.46M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.93M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.87M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $8.13M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.65M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.81M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.83M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $8.01M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $10.23M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $16.37M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $16.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.70M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.54M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.24M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.50M | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($133.78M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($128.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($123.34M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($116.41M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($107.70M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($100.89M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($93.52M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($86.00M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($78.57M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($73.38M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.98M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $8.72M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $14.76M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $14.22M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.52M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $743.4K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $2.64M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $3.60M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 6, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.45M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 78.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 75.85M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 69.27M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 68.12M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 64.14M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 49.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 33.83M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 33.16M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 30.42M | Apr 2, 2018 |